Latest Content


Dr. Jeremy Levin
0:53
FDA Leadership Turnover Explained
2 days ago
by
Mike Hollan(+1 more)
Ketan Mehta
Solving the ADHD Medication 'Crash' Problem
4 days ago
by
Mike Hollan(+1 more)
Market Watch Rx
1:19
Market Watch Rx: Eli Lilly Joins Top Gainers
7 days ago
by
Nicholas Jacobus
Will Shrank
0:49
Why the US Healthcare System is Fragmented
11 days ago
by
Mike Hollan(+1 more)
Why Patient Care is the Heart of Pharma Business
0:32
Why Patient Care is the Heart of Pharma Business
11 days ago
by
Mike Hollan(+1 more)
Market Watch Rx
1:15
Market Watch Rx: West Pharmaceutical Services Leads Gainers
14 days ago
by
Nicholas Jacobus
Jeff Golfman Send 123
0:32
Why 'Just-In-Time' Delivery is a Trap
15 days ago
by
Nicholas Jacobus(+1 more)
The United State's Regulatory Impact on Global Drug Launches
0:29
The United State's Regulatory Impact on Global Drug Launches
18 days ago
by
Mike Hollan(+1 more)
Market Watch Rx
1:08
Market Watch Rx: Johnson & Johnson Shares Slide
21 days ago
by
Nicholas Jacobus
Imran Kahn Johnson & Johnson
0:40
Real Hope: The Best Part of Being an Oncologist
22 days ago
by
Nicholas Jacobus(+1 more)

Aradhana Sarin: The CFO as a Catalyst

In becoming the first CFO to be named HBA Woman of the Year, AstraZeneca's Aradhana Sarin highlights how financial leadership now sits at the center of innovation, access and strategic transformation.

Aradhana Sarin: The CFO as a Catalyst

Pharmaceutical Executive: April 2026 Issue (PDF)

Click the title above for a link to open the Pharmaceutical Executive April 2026 issue in an interactive PDF format.

Pharmaceutical Executive: April 2026 Issue (PDF)

Why Advisory Committees Remain Essential in an Era of Complex Medicines

Dismissing the role of independent, outside experts in FDA decision-making weakens the drug review process.

Why Advisory Committees Remain Essential in an Era of Complex Medicines

New Federal Market Access Restrictions: Optimizing Manufacturer Strategies as PBMs Gain Power

Where PBMs fit into the new market access landscape, how pharma companies can respond and the questions that remain.

New Federal Market Access Restrictions: Optimizing Manufacturer Strategies as PBMs Gain Power

Trump Administration’s Leadership Carousel Across Key Agencies

Since the start of President Trump's second term, the FDA, CDC, CDER, and CBER have collectively cycled through more than a dozen leadership changes.

Trump Administration’s Leadership Carousel Across Key Agencies

Podcasts



All News

Pharmaceutical Executive Daily

In today's Pharmaceutical Executive Daily, Rigel Pharmaceuticals enters an exclusive global licensing agreement with Arvinas and Pfizer for Veppanu, Eli Lilly releases data from two late-phase trials showing patients maintained meaningful weight loss after transitioning from higher-dose injectable GLP-1 therapies, and Hope Mueller argues that true pharmaceutical expertise is defined not just by having answers but by recognizing when you need a reset.